Date: 2013-01-15
Type of information: Grant
Company: DBV Technologies (France) INRA (France)
Investors: ANR - French National Research Agency (France)
Amount: €600.000
Funding type: grant
Planned used: The grant has been awarded to develop a pediatric respiratory syncitial virus (RSV) vaccine.
Others: DBV Technologies and the French Institute for Agricultural Research-INRA (Molecular Virology and Immunology Unit, VIM-U892) have been awarded a research grant of nearly €600.000 from the French National Research Agency (ANR) to develop an innovative, efficient and safe pediatric ‘RSV’ bronchiolitis (‘RSV’) vaccine. RSV-NanoViaSkin is intended to become the world’s first non-invasive and adjuvant-free epicutaneous RSV pediatric vaccine.
VIM-U892 at INRA together with DBV Technologies will develop a new generation of pediatric vaccine delivered via the skin and targeting RSV bronchiolitis. The RSV-NanoViaSkin project aims at delivering a pre-clinical-proof of concept for a novel efficient and safe pediatric RSV vaccine that is able to find original solutions to all problems of current RSV vaccination strategies, in a 30-month study. The project aims at developing a full pre-clinical package in several animal models. The INRA innovation stands around a new immunogenic antigen (N-eF proteins), targeting CTL and neutralizing antibody-mediated immunity to RSV, using well characterized immunogenic nanostructures (Nring) decorated with epitopes from the fusion protein based on patented/published pre-clinical results, carried out by VIM-INRA. This vaccine will use the DBV\'s Viaskin® technology which allows epicutaneous application. This route of administration using Viaskin® enables to overcome the hurdles of interference of maternal antibodies and the immaturity of the immune system.
Therapeutic area: Infectious diseases
